Health ❯ Pharmaceuticals

Generic Drugs

Diabetes Treatment FDA Regulations Atorvastatin Semaglutide Market Dynamics Weight Loss US Government Programs Market Availability US Market Impact Supply Chain Drug Manufacturing Regulatory Issues Cost Plus Drugs Cardiovascular Medications Regulatory Processes Market Impact Biosimilars Market Access Drug Pricing Access to Medicines Multiple Sclerosis Treatments Diabetes Medications Market Trends Safety Reviews Company Profiles Weight Loss Medications Efficacy Concerns GLP-1 Receptor Agonists Global Production Cancer Treatment

FDA Class II Recall Issued for 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

Regulators urge patients to consult a clinician before making any medication changes.

FDA Class II Recall Targets 142,000 Bottles of Ascend’s Atorvastatin

FDA Confirms Safety Review of Mifepristone With No Regulatory Changes Yet

Chinese Weight-Loss Drug Suppliers Pivot to Generics as U.S. Crackdown Ends Copycat Boom